Horizon Pharma goes public at $9

Horizon Pharma ($HZNP) went public this morning, pricing 5.5 million shares at $9 a share. That's a little below the $10 to $12 range that it had hoped for, but not too bad considering some of the biotech IPOs that have floated at far bigger discounts so far this year. Horizon has also granted the underwriters a 30-day option to purchase up to an additional 825,000 shares at the initial public offering price to cover overallotments. Release

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.